Clinical trial · Observational
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma | PROBABILISTIC | 0.70 |
| Relapsed Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Relapsed glioblastoma | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients operated for primary and recurrent glioblastoma
- description
- Patients operated for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
- interventionNames
- Biological: Relapsed glioblastoma
Primary outcomes (1)
- measure
- Evaluation of metabolic changes involved in glioblastoma relapse
- timeFrame
- Up to 2 years after the start of the study
- description
- Relative abondance of metabolite and differential enzyme expression in a recurrence versus primary sample
Secondary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age \> 18 years * surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux Exclusion Criteria: * systemic therapy received for non-glioblastoma tumor
References
Publications (0)
Data not yet available